MARKET

CYTH

CYTH

Cyclo Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.99
-0.21
-2.92%
Opening 10:18 04/23 EDT
OPEN
7.11
PREV CLOSE
7.20
HIGH
7.15
LOW
6.95
VOLUME
29.68K
TURNOVER
--
52 WEEK HIGH
27.00
52 WEEK LOW
3.400
MARKET CAP
43.99M
P/E (TTM)
-1.1611
1D
5D
1M
3M
1Y
5Y
Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol® Cyclo in Alzheimers Disease
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today ...
Business Wire · 2d ago
Cyclo Therapeutics to proceed with IND filing for mid-stage alzheimer’s disease trial
Cyclo Therapeutics ([[CYTH]] +2.0%) has received feedback from the U.S. FDA supporting the company’s development strategy to submit an initial new drug application application for a Phase 2 study of Trappsol Cyclo in
Seekingalpha · 3d ago
DJ Cyclo Therapeutics to Move Ahead With IND Filing for Alzheimer's Treatment
Dow Jones · 3d ago
Cyclo Therapeutics To Proceed With IND Filing For Phase 2 Trial Using Intravenous Trappsol Cyclo In Alzheimer's Disease
FDA feedback supports Company's Phase 2 development strategy for Alzheimer's disease asset; IND filing on track for H2 2021 Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the
Benzinga · 3d ago
Cyclo Therapeutics on Track to File Investigational New Drug Application for Alzheimer's Disease Drug Candidate in H2
MT Newswires · 3d ago
Maxim Group Assigns a Buy Rating on Cyclo Therapeutics (CYTH)
In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to Cyclo Therapeutics (CYTH), with a price target of $25.00. The
SmarterAnalyst · 03/26 17:55
GME, RAD, CIDM and EVFM among midday movers
Gainers: ProQR Therapeutics (PRQR) +47%.Cellect Biotechnology (APOP) +47%.Houston Wire & Cable (HWCC) +38%.GameStop (GME) +29%.Koss (KOSS) +28%.Cinedigm (CIDM) +28%.F-star Therapeutics (FSTX) +26%.FreightCar America (RAIL) +24%.Polar Power (POLA) +20%.Immu...
Seekingalpha · 03/25 16:40
Cellect Biotechnology, ProQR Therapeutics leads healthcare gainers; Evolus, Rite Aid among major losers
Gainers: Cellect Biotechnology (APOP) +43%, ProQR Therapeutics (PRQR) +33%, Immutep Limited (IMMP) +29%, F-star Therapeutics (FSTX) +24%, Cancer Genetics (CGIX) +13%.Losers: Evolus (EOLS) -24%, Rite Aid (RAD) -24%, Evofem Biosciences (EVFM) -23%, Cyclo The...
Seekingalpha · 03/25 14:59
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CYTH. Analyze the recent business situations of Cyclo Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CYTH stock price target is 25.00 with a high estimate of 25.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 9
Institutional Holdings: 593.46K
% Owned: 9.43%
Shares Outstanding: 6.29M
TypeInstitutionsShares
Increased
0
0
New
8
593.36K
Decreased
0
0
Sold Out
1
300
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.04%
Pharmaceuticals & Medical Research
+0.38%
Key Executives
Chairman/Chief Executive Officer/Director
Nathan Fine
Chief Financial Officer
Joshua Fine
Chief Operating Officer/Chief Scientific Officer/Director/IR Contact Officer
Jeffrey Tate
Executive Vice President
George Fails
Senior Vice President
Sharon Hrynkow
Lead Director/Independent Director
Markus Sieger
Director
William Shanahan
Director
C. E. Rick Strattan
Director
Randall Toig
Independent Director
F. Patrick Ostronic
No Data
About CYTH
Cyclo Therapeutics, Inc. is a clinical stage biotechnology company. The Company develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease. The Company’s Trappsol Cyclo, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease. NPC is a fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. The Company also sells cyclodextrins and related products to the pharmaceutical, nutritional and other industries, primarily for use in diagnostics and specialty drugs. It serves chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors.

Webull offers kinds of Cyclo Therapeutics Inc stock information, including NASDAQ:CYTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYTH stock methods without spending real money on the virtual paper trading platform.